News
Events
Overview
Rationale for Immunodrugs™
Strategy
Board & Management
Industry Collaborations
Letter of the CEO
History
Overview
Immunodrug™ Platform
Immunodrug™ Manufacturing
Human Monoclonal Antibodies
Scientific Collaborations
Scientific Publications
Pipeline
Clinical Trials
Disease Areas
Overview
Ad-hoc Releases
Board & Management
Share Information
Bond Information
Analyst Coverage
Financial Calendar
Financial Reports
Corporate Governance
Stay Informed
Contact
Overview
Press Release Archive
Downloads
Picture Gallery
Contact
Preventing Chronic Diseases
– a Vital Investment
Cytos
Ad-hoc Releases
 
Cytos
Facts & Figures
 
Cytos Biotechnology AG
Wagistrasse 25
Postfach
8952 Schlieren
Switzerland
T +41 44 733 47 47
F +41 44 733 47 40
e-mail contact

Novel vaccines for chronic disease treatment and prevention

Cytos Biotechnology is dedicated to the discovery, development and commercialization
of a novel class of medicines – called Immunodrugs™. Immunodrugs™ are therapeutic
vaccines intended for use in the treatment and prevention of common chronic diseases
which afflict millions of people worldwide.

Important legal information: please read the disclaimer before proceeding.
News
2008, August 15:
Cytos Biotechnology and Pfizer enter into a research, option and license agreement for certain novel vaccines for a defined number of human diseases.


2008, July 24:
Cytos' second quarter report.
-
including an update on the two collaborative programs with Novartis in Alzheimer's disease and nicotine addiction.

2008, July 10:
CYT003-QbG10 monotherapy for the treatment of allergic diseases is safe and efficacious in placebo-controlled phase II study.